July 16, 2023
No Comments
News
RaeSedo Inc. awarded $3.4M STTR Grant to Develop New Asthma Therapies
RaeSedo Inc., a spin-out of the University of Arizona developing novel therapies for asthma, is pleased to announce the award of a Phase 2 Small Business Technology
November 17, 2022
No Comments
Small Peptide Derivatives Within the Carbohydrate Recognition Domain of SP-A2 Modulate Asthma Outcomes in Mouse Models and Human Cells
Surfactant Protein-A (SP-A) plays a crucial role in asthma, but genetic variation can lead to dysfunction. Researchers investigated a specific genetic change at position 223 in SP-A2, finding that individuals with the major variant (223Q) had better lung function, reduced inflammation, and improved asthma control. In mouse models and cells from asthmatic participants, they also showed that SP-A 223Q peptides had anti-inflammatory effects, suggesting their potential as therapeutic agents for asthma.
July 10, 2022
No Comments
SSTR awarded to RaeSedo, LLC: Development of surfactant protein A-derived peptidomimetics for the treatment of asthma
Drs. Monica Kraft and Julie Ledford received SSTR funding for a Phase I proposal to develop new, short peptide derivatives and mimetics of the active
July 17, 2020
No Comments
Drs. Monica Kraft and Julie Ledford Win $10K ‘Shark Tank’ Prize
The “sharks” ultimately invested in Monica Kraft, MD, and Julie Ledford, PhD, for their pitch on a new, inhaled therapeutic for the treatment of asthma and potentially even COPD, cystic fibrosis and pneumonia. The duo was presented with a check for $10,000 at the end of the competition.
February 23, 2019
No Comments
Surfactant Protein-A protects against IL-13-induced inflammation in asthma
The lung surfactant proteins are recognized as critical not only for their role in lowering lung surface tension but also in innate host defense. Reports
August 23, 2018
No Comments